Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07C 233/66 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
C07C 233/70 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
C07C 233/72 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 233/86 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
C07D 307/14 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 309/06 - Radicals substituted by oxygen atoms
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
C07D 319/12 - 1,4-DioxanesHydrogenated 1,4-dioxanes not condensed with other rings
2.
DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF
Disclosed are a double regulator for mGluR5 and HDAC6 and a use thereof. More specifically, disclosed are a compound that simultaneously regulates mGluR5 and HDAC6, and a use thereof as a therapeutic agent for movement disorders.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
3.
PHARMACEUTICAL COMPOSITION CONTAINING HIGH CONCENTRATION OF OPIRANSERIN
A pharmaceutical composition containing a high concentration of opiranserin is disclosed. More specifically, disclosed is a pharmaceutical composition comprising: opiranserin or a pharmaceutically acceptable salt thereof; a carrier selected from sodium benzoate, trisodium citrate, sodium salicylate and mixtures thereof; and a solvent for injection.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
4.
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
The present invention relates to a colonic purgative composition and a preparation method therefor, and more specifically, to a colonic purgative composition comprising sodium picosulfate, potassium sulfate and magnesium sulfate, and a preparation method therefor.
Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07C 233/66 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
C07C 233/70 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
C07C 233/72 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 233/86 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
C07D 307/14 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 309/06 - Radicals substituted by oxygen atoms
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
C07D 319/12 - 1,4-DioxanesHydrogenated 1,4-dioxanes not condensed with other rings
7.
METHOD OF PREVENTING OR TREATING POSTOPERATIVE PAIN
A method for treating or preempting pain including postoperative pain following a soft or hard tissue surgery is disclosed. Also disclosed is a method for reducing an postoperative analgesic need, including administering a compound of Formula (I) or a salt thereof.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
8.
DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF
A dual regulator for MGLUR5 and 5-HT2A receptor and a use thereof are disclosed. More specifically, a compound functioning as both a regulator of mGluR5 and an antagonist of 5-HT2A receptor, and a use thereof as a therapeutic agent for pain are disclosed.
C07D 213/04 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07C 231/08 - Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
C07C 233/32 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
9.
DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF
A dual regulator for MGLUR5 and 5-HT2A receptor and a use thereof are disclosed. More specifically, a compound functioning as both a regulator of mGluR5 and an antagonist of 5-HT2A receptor, and a use thereof as a therapeutic agent for pain are disclosed.
C07D 213/04 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07C 233/32 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
C07C 231/08 - Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
The present invention relates to a colonic purgative composition and a preparation method therefor, and more specifically, to a colonic purgative composition comprising sodium picosulfate, potassium sulfate and magnesium sulfate, and a preparation method therefor.
A method for treating or preempting pain including postoperative pain following a soft or hard tissue surgery is disclosed. Also disclosed is a method for reducing an postoperative analgesic need, including administering a compound of Formula (I) or a salt thereof.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 25/00 - Drugs for disorders of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes and veterinary preparations for the treatment of central nervous system diseases, pain, inflammation and skin disorders; dietetic foods and beverages adapted for medical purposes; dietetic foods and beverages adapted for veterinary purposes; sanitary preparations for medical purposes; biological preparations for medical purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; biochemical preparations for medical purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemical preparations for pharmaceutical purposes, for the treatment of central nervous system diseases, pain, inflammation and skin disorders; ferments for pharmaceutical purposes; biotechnological preparations for medical purposes, namely, analgesic preparations, anti-inflammatory preparations, antipyretic preparations, and anti-itch ointment; blood for medical purposes; chemical preparations for pharmaceutical purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemical preparations for medical or veterinary purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemical preparations for sanitary use; pharmaceutical preparations for immunity treatment; vitamin preparations; vaccines; dietary supplements; Therapeutic pharmaceutical for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, pain, inflammation and skin disorders; bacteriological preparations for medical and veterinary use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes and veterinary preparations for the treatment of central nervous system diseases, pain, inflammation and skin disorders; dietetic foods and beverages adapted for medical purposes; dietetic foods and beverages adapted for veterinary purposes; sanitary preparations for medical purposes; biological preparations for medical purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; biochemical preparations for medical purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemical preparations for pharmaceutical purposes, for the treatment of central nervous system diseases, pain, inflammation and skin disorders; ferments for pharmaceutical purposes; biotechnological preparations for medical purposes, namely, analgesic preparations, anti-inflammatory preparations, antipyretic preparations, and anti-itch ointment; blood for medical purposes; chemical preparations for pharmaceutical purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemical preparations for medical or veterinary purposes for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemical preparations for sanitary use; pharmaceutical preparations for immunity treatment; vitamin preparations; vaccines; dietary supplements; Therapeutic pharmaceutical for the treatment of central nervous system diseases, pain, inflammation and skin disorders; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, pain, inflammation and skin disorders; bacteriological preparations for medical and veterinary use
Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.
C07D 295/12 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 455/02 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberineAlkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
C07C 235/50 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 235/54 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
The present invention relates to a novel benzamide derivative and a pharmaceutical use thereof, and more specifically, to a novel benzamide derivative of formula 1 or a pharmaceutically acceptable salt thereof, and a composition containing same for the prevention and treatment of pain and itching. The benzamide derivative and the pharmaceutically acceptable salt according to the present invention have a remarkable effect on the suppression of pain. The benzamide derivative and the pharmaceutically acceptable salt have an effect on the suppression of pain not only in a neuropathic animal model but also in a formalin model and other pain-induced models, and thus can be used for the suppression of various kinds of pain such as nociceptive pain and chronic pain. Further, it is confirmed that the present invention has an antipruriginous effect on an itch model in which an established mechanism of pain and concept of treatment is applied, and therefore the antipruriginous composition is useful since the composition can be used for the radical treatment of atopy by suppressing and treating the early itching phase to prevent skin damage and inflammatory response after the scratching phase.
C07D 215/16 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
The present invention relates to a combination of effective substances causing synergistic effects of multiple targeting, and to uses thereof. More particularly, the present invention relates to a composition for a functional health food; to a cosmetic composition; to a pain alleviating composition; and to a composition for treating/preventing itching or atopic dermatitis, wherein each composition contains, as active ingredients, two or more substances selected from a group consisting of (a) an antagonist to a 5-HT2(5-hydroxtryptamine subtype 2) receptor; (b) an antagonist to a P2X receptor; and (c) any one of an agonist to a glycine receptor, an antagonist to a glycine transporter (GlyT), an agonist to a gamma-aminobutyric acid (GABA) receptor, and an antagonist to GABA transporter 1 (GABA1). The multi-targeting complex composition (specifically, natural product complex composition) has synergistic effects, and thus a treatment using a combination of individual substances may achieve increased biological effects from the mechanisms which the individual substances involve. Thus, the multi-targeting complex composition may not only remarkably alleviate pain but may also increase effects of: alleviating symptoms of skin diseases such as itching and atopic dermatitis; preventing or ameliorating depression; relaxation; skin pore reduction; ameliorating wrinkles; skin regeneration; skin health; skin condition recovery; whitening; preventing or ameliorating athlete's foot; scalp health recovery and regeneration; stimulation of hair growth; prevention of premature gray hair; improving teeth or ameliorating periodontal diseases; etc.
Disclosed therein are a method and a system for testing a neuropathic pain of a human testee. The method for testing the neuropathic pain includes the steps of : applying a pain and a tactile sense to the skin of a testee to cause a neuropathic pain to the testee and causing a pain relative to the tactile sense; and testing the level of the testee' s pain after the pain causing step.
Disclosed therein is a system for testing pain reactions for experimental animals. The testing system includes: a receiving part for receiving an experimental animal; a pain causing part for causing a pain to the experimental animal; a weight measuring part for measuring the extent of weight deflection of the received experimental animal; and a management server for datarizing the extent of weight deflection measured in the weight measuring part and managing and treating data of the extent of the weight deflection.
